Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment

References

• Jenkins HE, Yuen CM. The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis. 2018 May 1;22(5):3–6.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Geneva, Switzerland. The end TB strategy. 2015 [cited 2016 Nov 15]. Available at: http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1
   Google Scholar
• Dye C, Glaziou P, Floyd K, et al. Prospects for tuberculosis elimination. Annu Rev Public Health. 2013;34(1):271–286.
   PubMedGoogle Scholar
• Basu Roy R, Whittaker E, Seddon JA, et al. Tuberculosis susceptibility and protection in children. Lancet Infect Dis. 2019 Mar;19(3):e96–e108.
   PubMed Web of Science ®Google Scholar
• Wood R, Liang H, Wu H, et al. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis. 2010 Apr;14(4):406–412.
   PubMed Web of Science ®Google Scholar
• Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004 Apr;8(4):392–402.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Chiang SS, Esmail H, et al. The wonder years: what can primary school children teach us about immunity to mycobacterium tuberculosis? Front Immunol. 2018;9:2946.
   PubMedGoogle Scholar
• Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014 May 3;383(9928):1572–1579.
   PubMed Web of Science ®Google Scholar
• Zignol M, Sismanidis C, Falzon D, et al. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J. 2013 Sep;42(3):701–707.
   PubMed Web of Science ®Google Scholar
• Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J. 2012 Apr;31(4):347–352.
   PubMed Web of Science ®Google Scholar
• Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016 Oct;16(10):1193–1201.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Geneva, Switzerland. Global tuberculosis report. WHO/CDS/TB/2019.15. 2019 [cited 2019 Oct 22]. Available at: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
   Google Scholar
• Snow KJ, Sismanidis C, Denholm J, et al. The incidence of tuberculosis among adolescents and young adults: a global estimate. Eur Respir J. 2018 Feb;51(2):1702352.
   PubMed Web of Science ®Google Scholar
• Schaaf HS, Marais BJ, Carvalho I, et al. Challenges in childhood tuberculosis. In Migliori GB, Bothamley G, Duarte R, et al., editors. Tuberculosis (ERS Monograph). Sheffield:European Respiratory Society. 2018;234–262.
   Google Scholar
• Marais BJ, Gie RP, Obihara CC, et al. Well defined symptoms are of value in the diagnosis of childhood pulmonary tuberculosis. Arch Dis Child. 2005 Nov;90(11):1162–1165.
   PubMed Web of Science ®Google Scholar
• Marais BJ, Schaaf HS. Tuberculosis in children. Cold Spring Harb Perspect Med. 2014 Jul 18;4(9):a017855.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Godfrey-Faussett P, Hesseling AC, et al. Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis. 2012 Jun;12(6):469–479.
   PubMed Web of Science ®Google Scholar
• Dodd PJ, Prendergast AJ, Beecroft C, et al. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis. Thorax. 2017 Jun;72(6):559–575.
   PubMed Web of Science ®Google Scholar
• Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017 Jun 15;64(12):1670–1677.
   PubMed Web of Science ®Google Scholar
• Fox GJ, Oxlade O, Menzies D. Fluoroquinolone therapy for the prevention of multi-drug resistant tuberculosis in contacts: a cost-effectiveness analysis. Am J Respir Crit Care Med. 2015 Apr 27;192(2):229–237.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Fred D, Amanullah F, et al. Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. Policy Brief No. 1 Dubai, United Arab Emirates: Harvard Medical School Centre for Global Health Delivery - Dubai. 2015 [cited 2018 Jun 11]. Available at: http://sentinel-project.org/wp-content/uploads/2015/11/Harvard-Policy-Brief_revised-10Nov2015.pdf
   Google Scholar
• World Health Organization, Geneva, Switzerland. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. 2020 [cited 2020 Sept 8]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK554956/pdf/Bookshelf_NBK554956.pdf
   Google Scholar
• World Health Organization, Geneva, Switzerland. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management 2018 [cited 2018 Aug 6]. Available from: http://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/
   Google Scholar
• Chiang SS, Brooks MB, Jenkins HE, et al. Concordance of drug resistance profiles between persons with drug-resistant tuberculosis and their household contacts: a systematic review and meta-analysis. Clin Infect Dis. 2020 May 25:ciaa613. DOI:10.1093/cid/ciaa613. Epub ahead of print. PMID: 32448887
   Google Scholar
• Schaaf HS. Diagnosis and management of multidrug-resistant tuberculosis in children: a practical approach. Indian J Pediatr. 2019 Jan 17;86(8):717–724.
   PubMed Web of Science ®Google Scholar
• Detjen AK, DiNardo AR, Leyden J, et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respir Med. 2015 Mar 23;3(6):451–461.
   PubMed Web of Science ®Google Scholar
• Schaaf HS, Marais BJ. The Role of Xpert MTB/RIF Ultra in Diagnosing Pulmonary Tuberculosis in Children. Am J Respir Crit Care Med. 2019 Dec 15;200(12):1464–1465.
   PubMed Web of Science ®Google Scholar
• Zar HJ, Workman LJ, Prins M, et al. Tuberculosis diagnosis in children using xpert ultra on different respiratory specimens. Am J Respir Crit Care Med. 2019 Dec 15;200(12):1531–1538.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Geneva, Switzerland. The use of molecular line-probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy Guidance. WHO. 2016 [cited 2020 May 25]. Available at: https://www.who.int/tb/WHOPolicyStatementSLLPA.pdf?ua=1
   Google Scholar
• Cohen KA, Manson AL, Desjardins CA, et al. Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges. Genome Med. 2019;11(1):45.
   PubMedGoogle Scholar
• Outhred AC, Jelfs P, Suliman B, et al. Added value of whole-genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother. 2015 Apr;70(4):1198–1202.
   PubMed Web of Science ®Google Scholar
• Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93–e142.
   PubMed Web of Science ®Google Scholar
• Schaaf HS, Garcia-Prats AJ, McKenna L, et al. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. Expert Rev Clin Pharmacol. 2018 Mar;11(3):233–244.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Geneva, Switzerland. Rapid Communication: key changes to the treatment of drug-resistant tuberculosis. 2019 [cited 2020 Apr 23]. Available at: https://www.who.int/tb/publications/2019/WHO_RapidCommunicationMDRTB2019.pdf?ua=1
   Google Scholar
• Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018 Jul;15(7):e1002591.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahuja SD, Akkerman OW, et al. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDRTBt. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 Sep 8;392(10150):821–834.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Geneva, Switzerland. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019 [cited 2020 Feb 23]. Available at: https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1
   Google Scholar
• The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of Drug-Resistant Tuberculosis in Children: A Field Guide. Boston, USA: the Sentinel Project for Pediatric Drug-Resistant Tuberculosis; November 2018, Fourth edition. 2018 [cited 2020 Feb 23]. Available from: http://sentinel-project.org/wp-content/uploads/2019/02/Updated_DRTB-Field-Guide-2019-V3.pdf
   Google Scholar
• Dooley KE, Miyahara S, von Groote-bidlingmaier F, et al. Early bactericidal activity of different isoniazid doses for drug resistant tb (in hindsight): a randomized open-label clinical trial. Am J Respir Crit Care Med. 2020 Jan 16;201(11):1416–1424.
   Web of Science ®Google Scholar
• Seddon JA, Thee S, Jacobs K, et al. Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect. 2013 Apr;66(4):320–329.
   PubMed Web of Science ®Google Scholar
• Fregonese F, Ahuja SD, Akkerman OW, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018 Apr;6(4):265–275.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Geneva, Switzerland. WHO position statement on the use of delamanid for multidrug-resistant tuberculosis. 2018 [cited 2020 Apr 23]. Available at: https://www.who.int/tb/publications/2018/WHOPositionStatementDelamanidUse.pdf?ua=1
   Google Scholar
• Keam SJ. Pretomanid: first approval. Drugs. 2019 Nov;79(16):1797–1803.
   PubMed Web of Science ®Google Scholar
• Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020 Mar 5;382(10):893–902.
   PubMed Web of Science ®Google Scholar
• Working group on New TB Drugs, Stop TB Partnership. Clinical pipeline. [cited 2020 Apr 24]. Available at: https://www.newtbdrugs.org/pipeline/clinical
   Google Scholar
• Nachman S, Ahmed A, Amanullah F, et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis. 2015 Jun;15(6):711–720.
   PubMed Web of Science ®Google Scholar
• Martial LC, Kerkhoff J, Martinez N, et al. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children. Int J Antimicrob Agents. 2018 Jul;52(1):109–113.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis. [cited 2020 Apr 23]. Available at: https://clinicaltrials.gov/ct2/show/NCT02906007
   Google Scholar
• ClinicalTrials.gov. Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB. [cited 2020 Apr 23]. Available at: https://clinicaltrials.gov/ct2/show/NCT02354014
   Google Scholar
• Guglielmetti L, Le Du D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 2015 Jan 15;60(2):188–194.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A 6-month safety, efficacy, and PK trial of delamanid in pediatric patients with multidrug resistant tuberculosis. [cited 2020 Apr 23]. Available at: https://clinicaltrials.gov/ct2/show/NCT01859923
   Google Scholar
• ClinicalTrials.gov. Pharmacokinetic and safety trial to determine the appropriate dose for pediatric patients with multidrug resistant tuberculosis. cited 2020 Apr 23. Available at: https://clinicaltrials.gov/ct2/show/NCT01856634
   Google Scholar
• World Health Organization, Geneva, Switzerland. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance. 2016 [cited 2020 Apr 23]. Available at: https://www.who.int/tb/publications/Delamanid_interim_policy/en/
   Google Scholar
• World Health Organization, Geneva, Switzerland. Essential medicines and health products: prequalification of medicines. [cited 2020 Apr 24]. Available at: https://extranet.who.int/prequal/content/prequalified-lists/medicines
   Google Scholar
• Garcia-Prats AJ, Rose PC, Hesseling AC, et al. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis (Edinb). 2014 Mar;94(2):93–104.
   PubMed Web of Science ®Google Scholar
• Prieto LM, Santiago B, Del Rosal T, et al. Linezolid-containing treatment regimens for tuberculosis in children. Pediatr Infect Dis J. 2019 Mar;38(3):263–267.
   PubMed Web of Science ®Google Scholar
• Huynh J, Marais BJ. Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs. Ther Adv Infect Dis. 2019 Jan-Dec;6:2049936119864737.
   Web of Science ®Google Scholar
• World Health Organization, Geneva, Switzerland. Guidelines for the programmatic management of drug-resistant tuberculosis. update. 2011;WHO/HTM/TB/2011.6. 2011.
   Google Scholar
• Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010 Sep 1;182(5):684–692.
   PubMed Web of Science ®Google Scholar
• Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014 Oct;18(10):1188–1194.
   PubMed Web of Science ®Google Scholar
• Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019;380(13):1201–1213.
   PubMed Web of Science ®Google Scholar
• McKenna L. Tuberculosis Treatment Pipeline Report. Treatment Action Group. 2019 [cited 2020 Apr 23]. Available at: https://www.treatmentactiongroup.org/wp-content/uploads/2019/12/pipeline_tb_treatment_lm_final.pdf
   Google Scholar
• Young C, Walzl G, Du Plessis N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol. 2020 Mar;13(2):190–204.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol. 2015 Apr;15(4):255–263.
   PubMed Web of Science ®Google Scholar
• Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016 Apr;28(4):CD002244.
   Google Scholar
• Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci. 2010 Jun 15;293(1–2):12–17.
   PubMed Web of Science ®Google Scholar
• Mai NT, Dobbs N, Phu NH, et al. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. Elife. 2018 Feb 27;7:e33478. DOI:10.7554/eLife.33478. PMID:29482717.
   Web of Science ®Google Scholar
• Schoeman JF, Janse van Rensburg A, Laubscher JA, et al. The role of aspirin in childhood tuberculous meningitis. J Child Neurol. 2011 Aug;26(8):956–962.
   PubMed Web of Science ®Google Scholar
• Kroesen VM, Groschel MI, Martinson N, et al. Non-steroidal anti-inflammatory drugs as host-directed therapy for tuberculosis: a systematic review. Front Immunol. 2017;8:772.
   PubMed Web of Science ®Google Scholar
• van Toorn R, Du Plessis AM, Schaaf HS, et al. Clinicoradiologic response of neurologic tuberculous mass lesions in children treated with thalidomide. Pediatr Infect Dis J. 2015 Feb;34(2):214–218.
   PubMed Web of Science ®Google Scholar
• Frank DJ, Horne DJ, Dutta NK, et al. Remembering the host in tuberculosis drug development. J Infect Dis. 2019 Apr 19;219(10):1518–1524.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Perez-Velez CM, Schaaf HS, et al. Consensus statement on research definitions for drug-resistant tuberculosis in children. J Pediatric Infect Dis Soc. 2013 Jun;2(2):100–109.
   PubMedGoogle Scholar
• Crook AM, Turkova A, Musiime V, et al. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. BMC Med. 2016 Mar;23(14):50.
   Google Scholar
• Mesfin YM, Hailemariam D, Biadglign S, et al. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLoS ONE. 2014;9(1):e82235.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Hesseling AC, Marais BJ, et al. Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinb). 2012 Jan;92(1):9–17.
   PubMed Web of Science ®Google Scholar
• Brill MJ, Svensson EM, Pandie M, et al. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Int J Antimicrob Agents. 2017 Feb;49(2):212–217.
   PubMed Web of Science ®Google Scholar
• Coyne KM, Pozniak AL, Lamorde M, et al. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS. 2009 Feb 20;23(4):437–446.
   PubMed Web of Science ®Google Scholar
• Harausz EP, Garcia-Prats AJ, Seddon JA, et al. New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations. Am J Respir Crit Care Med. 2017 May 15;195(10):1300–1310.
   PubMed Web of Science ®Google Scholar
• Isaakidis P, Casas EC, Das M, et al. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015 Aug;19(8):969–978.
   PubMed Web of Science ®Google Scholar
• Chem ED, Van Hout MC, Hope V. Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis. BMC Infect Dis. 2019 Aug 16;19(1):723.
   PubMed Web of Science ®Google Scholar
• Hong H, Budhathoki C, Farley JE. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection. Int J Tuberc Lung Dis. 2018 Jun 1;22(6):667–674.
   PubMed Web of Science ®Google Scholar
• Hicks RM, Padayatchi N, Shah NS, et al. Malnutrition associated with unfavorable outcome and death among South African MDR-TB and HIV co-infected children. Int J Tuberc Lung Dis. 2014 Sep;18(9):1074–1083.
   PubMed Web of Science ®Google Scholar
• Jaganath D, Mupere E. Childhood tuberculosis and malnutrition. J Infect Dis. 2012 Dec 15;206(12):1809–1815.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Geneva, Switzerland. Nutritional care and support for patients with tuberculosis. 2013 [cited 2020 May 5]. Available at: https://apps.who.int/iris/bitstream/handle/10665/94836/9789241506410_eng.pdf?sequence=1
   Google Scholar
• Chiang SS, Park S, White EI, et al. Using changes in weight-for-age z score to predict effectiveness of childhood tuberculosis therapy. J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):150–158. DOI:10.1093/jpids/piy138. PMID:30715497.
   PubMed Web of Science ®Google Scholar
• Grobler L, Nagpal S, Sudarsanam TD, et al. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev. 2016(6). doi:10.1002/14651858.CD006086.pub4.
   PubMed Web of Science ®Google Scholar
• Tegegne BS, Mengesha MM, Teferra AA, et al. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis. Syst Rev. 2018 Oct 15;7(1):161.
   PubMedGoogle Scholar
• Webb EA, Hesseling AC, Schaaf HS, et al. High prevalence of Mycobacterium tuberculosis infection and disease in children and adolescents with type 1 diabetes mellitus. Int J Tuberc Lung Dis. 2009 Jul;13(7):868–874.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xin H, Li X, et al. A dose-response relationship of smoking with tuberculosis infection: A cross-sectional study among 21008 rural residents in China. PLoS ONE. 2017;12(4):e0175183.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang Y, Shi G, et al. Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study. BMC Public Health. 2016 Jan;16(16):42.
   PubMedGoogle Scholar
• Whittaker E, Kampmann B. Perinatal tuberculosis: new challenges in the diagnosis and treatment of tuberculosis in infants and the newborn. Early Hum Dev. 2008 Dec;84(12):795–799.
   PubMed Web of Science ®Google Scholar
• Cantwell MF, Shehab ZM, Costello AM, et al. Brief report: congenital tuberculosis. N Engl J Med. 1994 Apr 14;330(15):1051–1054.
   PubMed Web of Science ®Google Scholar
• Skevaki CL, Kafetzis DA. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues. Paediatr Drugs. 2005;7(4):219–234.
   PubMedGoogle Scholar
• Loveday M, Hughes J, Sunkari B, et al. Maternal and infant outcomes among pregnant women treated for multidrug/rifampicin-resistant tuberculosis in South Africa. Clin Infect Dis. 2020 Mar 6:ciaa189. DOI:10.1093/cid/ciaa189. Epub ahead of print. PMID:32141495.
   PubMedGoogle Scholar
• Mittal H, Das S, Faridi MM. Management of newborn infant born to mother suffering from tuberculosis: current recommendations & gaps in knowledge. Indian J Med Res. 2014 Jul;140(1):32–39.
   PubMedGoogle Scholar
• Cohen KA, Manson AL, Abeel T, et al. Extensive global movement of multidrug-resistant M. tuberculosis strains revealed by whole-genome analysis. Thorax. 2019 Sep;74(9):882–889.
   PubMed Web of Science ®Google Scholar
• Boyd AT, Cookson ST. TB control in humanitarian emergencies: lessons from the Syria displacement crisis. J Clin Tuberc Other Mycobact Dis. 2019 Feb;14:31–35.
   PubMedGoogle Scholar
• Pareek M, Greenaway C, Noori T, et al. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med. 2016 Mar;23(14):48.
   Google Scholar
• Hayward S, Harding RM, McShane H, et al. Factors influencing the higher incidence of tuberculosis among migrants and ethnic minorities in the UK. F1000Res. 2018;7:461.
   PubMedGoogle Scholar
• Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis. 2013;13(6):529–539.
   PubMed Web of Science ®Google Scholar
• Marais BJ, Tadolini M, Zignol M, et al. Paediatric tuberculosis in Europe: lessons from Denmark and inclusive strategies to consider. Eur Respir J. 2014 Mar;43(3):678–684.
   PubMed Web of Science ®Google Scholar
• Snow KJ, Cruz AT, Seddon JA, et al. Adolescent tuberculosis. Lancet Child Adolesc Health. 2020 Jan;4(1):68–79.
   PubMedGoogle Scholar
• Patterson B, Morrow CD, Kohls D, et al. Mapping sites of high TB transmission risk: integrating the shared air and social behaviour of TB cases and adolescents in a South African township. Sci Total Environ. 2017 Apr;1(583):97–103.
   Google Scholar
• Stevens H, Ximenes RAA, Dantas OMS, et al. Risk factors for tuberculosis in older children and adolescents: a matched case–control study in Recife, Brazil. Emerg Themes Epidemiol. 2014;11(1):1.
   PubMedGoogle Scholar
• Enane LA, Lowenthal ED, Arscott-Mills T, et al. Loss to follow-up among adolescents with tuberculosis in Gaborone, Botswana. Int J Tuberc Lung Dis. 2016 Oct;20(10):1320–1325.
   PubMed Web of Science ®Google Scholar
• Chiang CY, Bai KJ, Lee CN, et al. Inconsistent dosing of anti-tuberculosis drugs in Taipei, Taiwan. Int J Tuberc Lung Dis. 2010 Jul;14(7):878–883.
   PubMed Web of Science ®Google Scholar
• Moore BK, Anyalechi E, van der Walt M, et al. Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa, 2005-2010. Int J Tuberc Lung Dis. 2015 Jun;19(6):663–669.
   PubMed Web of Science ®Google Scholar
• Allwood B, van der Zalm M, Makanda G, et al. The long shadow post-tuberculosis. Lancet Infect Dis. 2019;19(11):1170–1171.
   PubMed Web of Science ®Google Scholar
• Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration. 2013;86(1):76–85.
   PubMed Web of Science ®Google Scholar
• Byrne AL, Marais BJ, Mitnick CD, et al. Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis. ERJ Open Res. 2017;3(3):00026–2017.
   PubMedGoogle Scholar
• Eshetie S, Gizachew M, Dagnew M, et al. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017 Mar 20;17(1):219.
   PubMedGoogle Scholar
• Ranzani OT, Rodrigues LC, Bombarda S, et al. Long-term survival and cause-specific mortality of patients newly diagnosed with tuberculosis in São Paulo state, Brazil, 2010–15: a population-based, longitudinal study. Lancet Infect Dis. 2020;20(1):123–132.
   PubMed Web of Science ®Google Scholar
• Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014 Oct;14(10):947–957.
   PubMed Web of Science ®Google Scholar
• Seddon JA, Visser DH, Bartens M, et al. Impact of drug resistance on clinical outcome in children with tuberculous meningitis. Pediatr Infect Dis J. 2012 Jul;31(7):711–716.
   PubMed Web of Science ®Google Scholar
• Alene KA, Clements ACA, McBryde ES, et al. Mental health disorders, social stressors, and health-related quality of life in patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Infect. 2018 Nov;77(5):357–367.
   PubMed Web of Science ®Google Scholar
• Thomas BE, Shanmugam P, Malaisamy M, et al. Psycho-socio-economic issues challenging multidrug resistant tuberculosis patients: a systematic review. PLoS ONE. 2016;11(1): e0147397.
   PubMed Web of Science ®Google Scholar
• Franck C, Seddon JA, Hesseling AC, et al. Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study. BMC Infect Dis. 2014;14(1):426.
   PubMedGoogle Scholar
• Wingfield T, Boccia D, Tovar M, et al. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru. PLoS Med. 2014 Jul;11(7):e1001675.
   PubMed Web of Science ®Google Scholar
• Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J. 2014 Jun;43(6):1763–1775.
   PubMed Web of Science ®Google Scholar
• van den Hof S, Collins D, Hafidz F, et al. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan. BMC Infect Dis. 2016 Sept 05;16(1):470.
   PubMedGoogle Scholar
• Mudzengi D, Sweeney S, Hippner P, et al. The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa. Health Policy Plan. 2017 Nov 1;32(suppl_4):iv48–iv56.
   PubMedGoogle Scholar
• Loveday M, Sunkari B, Master I, et al. Household context and psychosocial impact of childhood multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2018 Jan 1;22(1):40–46.
   PubMed Web of Science ®Google Scholar
• Treatment Action Group, Sentinel Project on Pediatric Drug-Resistant Tuberculosis. We Can Heal: prevention, Diagnosis, Treatment, Care, and Support: addressing Drug-Resistant Tuberculosis in Children. 2013 [cited 2020 Apr 28]. Available at: https://www.treatmentactiongroup.org/wp-content/uploads/2013/03/tag-we-can-heal-final-sm_0.pdf
   Google Scholar
• van Hoorn R, Jaramillo E, Collins D, et al. The effects of psycho-emotional and socio-economic support for tuberculosis patients on treatment adherence and treatment outcomes - a systematic review and meta-analysis. PLoS ONE. 2016;11(4):e0154095.
   PubMed Web of Science ®Google Scholar
• Weaver MS, Lonnroth K, Howard SC, et al. Interventions to improve adherence to treatment for paediatric tuberculosis in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2015 Oct 1;93(10):700–711B.
   PubMed Web of Science ®Google Scholar
• Courtwright A, Turner AN. Tuberculosis and stigmatization: pathways and interventions. Public Health Rep. 2010;125(4_suppl):34–42.
   PubMedGoogle Scholar
• Velayutham B, Nair D, Ramalingam S, et al. Setting priorities for a research agenda to combat drug-resistant tuberculosis in children. Public Health Action. 2015 Dec 21;5(4):222–235.
   PubMed Web of Science ®Google Scholar